Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2024-03-12 Capital/Financing Update
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Launch of equity placing of approximately US$10m
Capital/Financing Update Classification · 98% confidence The document is an official announcement released via RNS (RNS Number: 4874G) on March 12, 2024. The core subject is the 'launch of an equity placing of Ordinary Shares of approximately US$10 million'. This clearly describes a financing activity involving the issuance of new shares to raise capital. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the specific nature of the content (equity placing/fundraising) makes CAP the most precise classification over the general 'RNS' fallback. The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-03-12 English
FORM 8 (OPD) - Renalytix plc
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER' and references 'Rules 8.1 and 8.2 of the Takeover Code (the "Code")'. This type of disclosure relates to insider/director dealings or ownership changes specifically in the context of a takeover offer. While it involves director interests (Section 3), its primary function is mandated by takeover regulations regarding position disclosure. This specific form (Form 8) is a specialized regulatory filing related to takeover activity, which is best categorized under the general 'Regulatory Filings' (RNS) as it doesn't fit the specific 'Director's Dealing' (DIRS) which usually refers to standard insider transaction reports (like Form 4 or DTR 3 filings), nor does it fit 'M&A Activity' (TAR) which is broader merger announcements. Given the context of RNS distribution and the specific nature of the disclosure mandated by the Takeover Code, RNS is the most appropriate general regulatory bucket, although DIRS is a close secondary consideration. However, since the document is a direct regulatory filing disseminated via RNS, RNS is chosen as the primary classification.
2024-03-08 English
Approach from Possible Strategic Acquiror
M&A Activity Classification · 100% confidence The document is an RNS announcement dated March 4, 2024, concerning an unsolicited approach, the launch of a Formal Sale Process, and financing updates for Renalytix plc. The text explicitly references the 'City Code on Takeovers and Mergers' (Takeover Code), Rule 2.4, Rule 2.7, and Rule 2.6, which are hallmarks of M&A activity or takeover bids. The core subject is the evaluation of a possible sale of the company or its assets via a 'Formal Sale Process'. This directly aligns with the definition of M&A Activity (TAR). Although it is a regulatory announcement (RNS), the specific content is about a takeover/sale process, making TAR the most precise classification over the general RNS fallback.
2024-03-04 English
Grant of Share Options - replacement
Remuneration Information Classification · 99% confidence The document is an amendment to a previous announcement regarding the 'Grant of Share Options' to directors and executives. It details the grant of options, the individuals involved (Chairman and Non-Executive Directors), the exercise price, and the vesting schedule. This type of filing, which reports personal share transactions or grants of options to directors and executives, directly corresponds to the definition of 'Director's Dealing' (DIRS). Although it is an amendment to a previous filing, the core subject matter is insider share transactions/grants, not a general regulatory announcement (RNS) or a general capital change (SHA).
2024-03-01 English
US Government coverage expanded
Regulatory Filings Classification · 100% confidence The document begins with an RNS Number and is dated February 29, 2024. It announces significant business developments regarding US Government coverage expansion for the kidneyintelX.dkd test and updates on Medicare coverage proceedings (NGS Open Meeting, LCD finalization). The text is structured as a press release detailing operational and regulatory progress, rather than a formal statutory filing like a 10-K or a comprehensive quarterly report (IR). It is a general announcement disseminated via the RNS system. Since it is a broad regulatory/business update that doesn't fit the specific categories like ER (Earnings Release), DIV (Dividend Notice), or CAP (Financing Update), the most appropriate classification is the general regulatory announcement category, RNS.
2024-02-29 English
Half Year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half Year Report' for Renalytix plc for the period ended December 31, 2023. It contains substantive financial data, including an income statement, revenue analysis, administrative costs, and a management discussion (Chairman & CEO's Joint Statement). As it covers a period shorter than a full fiscal year and includes actual financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2024
2024-02-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.